Pharmaceutical documents are among the most consequential texts a translation agency handles. A submission to the European Medicines Agency, a clinical trial protocol, a patient information leaflet or a labelling file each carries regulatory and safety implications that tolerate no approximation. The terminology must be correct. The format must comply with the applicable guideline. The translation must be verifiable.<\/p>\n\n\n\n
Pharmaceutical translation<\/strong> in Belgium operates within a dense regulatory framework: the Federal Agency for Medicines and Health Products (FAMHP\/AFMPS), the European Medicines Agency (EMA), ICH guidelines, EU Clinical Trials Regulation (CTR 536\/2014) and the MDR 2017\/745 for pharmaceutical-adjacent medical devices. Every document must reflect the terminology validated by the relevant regulator, in the language it will be submitted in. BeTranslated, a specialised translation agency<\/a> based in Li\u00e8ge, structures each pharmaceutical translation project around these regulatory requirements.<\/p>\n\n\n\n To request a quote, submit your files online<\/a>.<\/p>\n\n\n\n The EMA and FAMHP publish approved terminology for pharmacological concepts, dosing instructions, adverse event reporting and safety terminology in each of the EU’s official languages. A translation that deviates from this approved terminology, even subtly, may be rejected or returned for revision, delaying an authorisation process by months. The translator must know not only the language but the exact terms that the regulator expects to see in each section of the dossier.<\/p>\n\n\n\n Patient information leaflets (PILs) and summary of product characteristics (SmPCs) are read by pharmacists, healthcare professionals and patients who act on them directly. A misrendered dosing instruction, a confusingly translated contraindication or an unclear adverse event description can contribute to medication errors. Belgium’s obligations under Directive 2001\/83\/EC require that PILs be legible, understandable and written in the official language of the member state where the product is marketed.<\/p>\n\n\n\n Pharmaceutical and chemical products represent 25.9% of Belgium’s exports \u2014 \u20ac90 billion in 2024<\/p>\n Belgium is home to Janssen Pharmaceutica, UCB, Galapagos and among the largest pharma clusters in Europe<\/p>\n According to the SPF Economy, pharmaceutical and chemical products are Belgium’s single largest export category, reaching \u20ac90 billion in 2024 (25.9% of total goods exports). Major players including Janssen Pharmaceutica (Johnson & Johnson), UCB, Galapagos, GSK Vaccines and Pfizer all have significant Belgian operations. Each clinical trial conducted in Belgium, each product authorised by the FAMHP, and each label printed for the Belgian market generates pharmaceutical documentation that must be translated accurately into the relevant official languages.<\/p>\n Source: SPF Economy, Belgian foreign trade 2024<\/a><\/p>\n<\/div>\n\n\n\n Products marketed in Belgium must carry labelling and product information in French, Dutch and German. For clinical trial submissions under the EU CTR, the trial protocol and consent forms must be translated into the language of each participating member state. Managing this multilingual obligation for a multinational trial or a Belgian licensing dossier requires a translation partner with both language coverage and regulatory expertise.<\/p>\n\n\n\n Pharmaceutical files are assigned to linguists with academic or professional backgrounds in pharmacy, biochemistry, regulatory affairs or clinical research. Several have worked as regulatory affairs officers or medical writers before transitioning to translation. All translate into their mother tongue. Profiles are available on the professional translators<\/a> page.<\/p>\n\n\n\n Every pharmaceutical translation undergoes independent proofreading<\/a> by a second specialist (ISO 17100). Confidential clinical data and unpublished compound information are handled under strict non-disclosure agreements and full GDPR compliance. Rates<\/a> are quoted in a detailed proposal before project launch.<\/p>\n\n\n\n A regulatory dossier, PIL or clinical trial document to translate?<\/p>\nWhy pharmaceutical translation requires specialist expertise<\/h2>\n\n\n\n
Regulatory terminology is not optional<\/h3>\n\n\n\n
Patient safety starts with clear communication<\/h3>\n\n\n\n
Pharmaceutical documents we translate<\/h2>\n\n\n\n
\n
Belgium’s pharmaceutical sector and its translation demands<\/h2>\n\n\n\n
Three languages, three regulatory audiences<\/h3>\n\n\n\n
How BeTranslated handles pharmaceutical translation<\/h2>\n\n\n\n
Linguists with pharmaceutical and regulatory backgrounds<\/h3>\n\n\n\n
Independent review, ISO 17100 and confidentiality<\/h3>\n\n\n\n